NASDAQ:ASMB

Assembly Biosciences Competitors

$4.10

-0.18 (-4.21 %)

(As of 04/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.07

Now: $4.10▼

$4.31

50-Day Range

$4.25

MA: $4.64▼

$5.17

52-Week Range

$4.07

Now: $4.10▼

$27.84

Volume686,367 shs

Average Volume1.23 million shs

Market Capitalization$164.24 million

P/E RatioN/A

Dividend YieldN/A

Beta0.61

Assembly Biosciences (NASDAQ:ASMB) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying ASMB stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Assembly Biosciences, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Assembly Biosciences vs. Johnson & Johnson Stock

Assembly Biosciences (NASDAQ:ASMB) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Johnson & Johnson's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-60.14%	-18.75%	-15.89%
Johnson & Johnson	21.01%	34.64%	13.40%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Johnson & Johnson, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	2	4	0	2.67
Johnson & Johnson	0	3	11	0	2.79

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Johnson & Johnson has a consensus target price of $182.6154, suggesting a potential upside of 12.25%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Johnson & Johnson.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Johnson & Johnson's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10
Johnson & Johnson	$82.06 billion	5.22	$15.12 billion	$8.68	18.74

Johnson & Johnson has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Summary

Johnson & Johnson beats Assembly Biosciences on 10 of the 14 factors compared between the two stocks.

Assembly Biosciences vs. Pfizer Stock

Assembly Biosciences (NASDAQ:ASMB) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Pfizer's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-60.14%	-18.75%	-15.89%
Pfizer	17.85%	24.88%	9.32%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Pfizer, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	2	4	0	2.67
Pfizer	0	10	3	0	2.23

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Pfizer has a consensus target price of $38.5714, suggesting a potential downside of 0.92%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Pfizer.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Pfizer's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10
Pfizer	$51.75 billion	4.20	$16.27 billion	$2.95	13.20

Pfizer has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Assembly Biosciences on 8 of the 14 factors compared between the two stocks.

Assembly Biosciences vs. Merck & Co., Inc. Stock

Assembly Biosciences (NASDAQ:ASMB) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Assembly Biosciences and Merck & Co., Inc.'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-60.14%	-18.75%	-15.89%
Merck & Co., Inc.	24.33%	53.83%	16.83%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and Merck & Co., Inc., as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	2	4	0	2.67
Merck & Co., Inc.	0	2	11	0	2.85

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Merck & Co., Inc. has a consensus target price of $96.2727, suggesting a potential upside of 23.97%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Merck & Co., Inc..

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Earnings & Valuation

This table compares Assembly Biosciences and Merck & Co., Inc.'s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10
Merck & Co., Inc.	$46.84 billion	4.20	$9.84 billion	$5.19	14.96

Merck & Co., Inc. has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Summary

Merck & Co., Inc. beats Assembly Biosciences on 9 of the 14 factors compared between the two stocks.

Assembly Biosciences vs. AbbVie Stock

Assembly Biosciences (NASDAQ:ASMB) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Assembly Biosciences and AbbVie's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-60.14%	-18.75%	-15.89%
AbbVie	18.16%	439.24%	13.22%

Analyst Ratings

This is a summary of current recommendations for Assembly Biosciences and AbbVie, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0	2	4	0	2.67
AbbVie	1	2	13	0	2.75

Assembly Biosciences presently has a consensus target price of $11.50, suggesting a potential upside of 180.49%. AbbVie has a consensus target price of $115.75, suggesting a potential upside of 6.57%. Given Assembly Biosciences' higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than AbbVie.

Earnings & Valuation

This table compares Assembly Biosciences and AbbVie's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10
AbbVie	$33.27 billion	5.76	$7.88 billion	$8.94	12.15

AbbVie has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Assembly Biosciences shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 7.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Assembly Biosciences has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Summary

AbbVie beats Assembly Biosciences on 10 of the 14 factors compared between the two stocks.

Assembly Biosciences vs. Eli Lilly and Stock

Eli Lilly and (NYSE:LLY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Eli Lilly and and Assembly Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eli Lilly and	24.01%	166.45%	15.18%
Assembly Biosciences	-60.14%	-18.75%	-15.89%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Assembly Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and	0	4	11	0	2.73
Assembly Biosciences	0	2	4	0	2.67

Eli Lilly and presently has a consensus price target of $196.40, suggesting a potential upside of 3.56%. Assembly Biosciences has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Assembly Biosciences' higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Eli Lilly and.

Valuation and Earnings

This table compares Eli Lilly and and Assembly Biosciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and	$22.32 billion	8.15	$8.32 billion	$6.04	31.40
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10

Eli Lilly and has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 92.2% of Assembly Biosciences shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 7.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Eli Lilly and has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Summary

Eli Lilly and beats Assembly Biosciences on 9 of the 14 factors compared between the two stocks.

Assembly Biosciences vs. Bristol-Myers Squibb Stock

Bristol-Myers Squibb (NYSE:BMY) and Assembly Biosciences (NASDAQ:ASMB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Bristol-Myers Squibb and Assembly Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol-Myers Squibb	-0.11%	27.48%	10.77%
Assembly Biosciences	-60.14%	-18.75%	-15.89%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bristol-Myers Squibb and Assembly Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol-Myers Squibb	0	2	13	1	2.94
Assembly Biosciences	0	2	4	0	2.67

Bristol-Myers Squibb presently has a consensus price target of $74.60, suggesting a potential upside of 13.72%. Assembly Biosciences has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Given Assembly Biosciences' higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Bristol-Myers Squibb.

Valuation and Earnings

This table compares Bristol-Myers Squibb and Assembly Biosciences' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol-Myers Squibb	$26.15 billion	5.61	$3.44 billion	$4.69	13.99
Assembly Biosciences	$15.96 million	10.29	$-97,630,000.00	($3.72)	-1.10

Bristol-Myers Squibb has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 92.2% of Assembly Biosciences shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 7.1% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Assembly Biosciences on 10 of the 15 factors compared between the two stocks.